About Candel Therapeutics
Candel Therapeutics is a publicly listed company based in United States founded in 1999. It operates as a viral immunotherapies are developed for cancer treatment. Candel Therapeutics has raised $110.3 million across 14 funding rounds from investors including HHS, Sands Capital Ventures and Northpond Ventures. The company has 38 employees. Its chief executive is Aguilar Estuardo. Candel Therapeutics offers products and services including CAN-2409 and CAN-3110. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its competitors include Replimune, TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience and GigaGen and 3 more; 8 of its 8 listed competitors have raised funding.
Company details
Candel Therapeutics was founded in 1999 in the United States. Focus is placed on the biotechnology sector, where viral immunotherapies are created to target cancer. These therapies work by lysing tumor cells to release antigens and neoantigens, which trigger in situ vaccination and activate both innate and adaptive immune responses. Operations center on research and development of such immunotherapies, with leadership provided by CEO Aguilar Estuardo.
- Headquarters United States
- Employees 38
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website candeltx.com
- Social LinkedIn X
- Legal Name Candel Therapeutics, Inc.
- Net Profit-$38.18 M (USD)30.8as on Dec 31, 2025
- EBITDA-$47.42 M (USD)-46.45as on Dec 31, 2025
- Total Equity Funding$110.3M (USD)
in 14 rounds
- Latest Funding Round$22.5M (USD), Series C
Apr 2019
- InvestorsHHS
& 5 more
- Employee Count38
Products & Services of Candel Therapeutics
Candel Therapeutics offers a comprehensive portfolio of products and services, including CAN-2409 and CAN-3110.
Mechanism of action for targeted cancer treatment using viral agents.
Another viral mechanism designed for cancer immunotherapy applications.
Funding Insights of Candel Therapeutics
Candel Therapeutics has successfully raised a total of $110.3M across 14 strategic funding rounds. The most recent funding activity was a Series C round of $22.5 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $110.3M
- Total Rounds 14
- Last Round Series C — $22.5M
- First Round $1.3M
(Jun 2004)
- Investors Count 6
Latest 10 of 14 funding rounds of Candel Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2019 | $22.5M | Series C | – | – | |
| Jan 2019 | $28.7M | Series B | – | PBM Capital | – |
| Nov 2018 | $28.7M | Series B | – | – | – |
| Sep 2016 | $14M | Series A | – | National Securities Corporation | – |
| Sep 2016 | $14.2M | Series A | – | – | – |
| Dec 2015 | $2.3M | Grant | – | – | |
| Dec 2015 | $2.2M | Seed | – | – | – |
| Sep 2014 | $224,999 | Grant | – | – | |
| Feb 2014 | $7.3M | Grant | – | – | |
| May 2011 | $500,000 | Grant | – | – |
6 investors in total: 6 institutional.
Investors in Candel Therapeutics
Candel Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Sands Capital Ventures and Northpond Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth stage tech & life sciences focused VC Firm investing in Asia and the US | – | sandscapitalventures.com | Arlington, United States | |
Venture capital firm investing in life sciences & tech sectors | – | npv.vc | Cambridge, United States | |
PE firm investing in the US | – | pbmcap.com | Charlottesville, United States | |
Life sciences innovation is supported through funding and programs. | – | masslifesciences.com | Waltham, United States | |
- | – | nationalsecurities.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Candel Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Candel Therapeutics
56 people are tracked at Candel Therapeutics (18 in leadership, 22 in board & advisors, 16 in team); the tracked headcount is 38.
| Name | Role | Group |
|---|---|---|
Aguilar Estuardo | CEO | Leadership |
W. Garrett Nichols | Chief Medical Officer | Leadership |
Seshu Tyagarajan | Chief Technical & Development Officer | Leadership |
Todd Lefurge | Director, Clinical Data Management | Leadership |
Ileen Winick | Chief People Officer | Leadership |
Paul Peter Tak | President, CEO & Board Member | Leadership |
Susan Stewart | Chief Regulatory Officer | Leadership |
Ted Jenkins | Vice President, Investor Relations And Business Development | Leadership |
Jennifer Jumper | Senior Director, Information Technology | Leadership |
Charles Schoch | Interim Chief Financial Officer | Leadership |
Shalini Choudhary | Director Of IT | Leadership |
Anne R. Diers | Vice President, Research | Leadership |
Shangbang Rao | Senior Director, Biostatistics | Leadership |
Andrea Manzanera | Vp, Clinical Research & Pharmacovigilance | Leadership |
Francesca Barone | Chief Scientific Officer | Leadership |
María Lucía Silva Polanco | Associate Director Clinical Research & PV | Leadership |
Mahua Roychoudhury | Vice President Clinical Operations | Leadership |
Marcos Ramírez-Márquez | Director Of Clinical Research | Leadership |
Patrick Y. Wen | Scientific Advisor | Board & advisors |
Udi Meirav | Director | Board & advisors |
36 more people are available in the full profile.
Complete people profiles for Candel Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Candel Therapeutics
Candel Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CADL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Jul 2021
- Listed onNASDAQ: CADL
- Listed entityCandel Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS1374041093
- Share price$9.27 (-5.21% on the day) · 2026-10-13
- Market capitalisation$709.3M
- EPS (diluted, trailing year)$-1.41
- Volume (last session)1,133,162
Financials of Candel Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$38.2M | -$47.4M |
| 2024 | – | -$55.2M | -$32.4M |
| 2023 | – | -$37.9M | -$37.2M |
| 2022 | $125,000 | -$18.8M | -$33.7M |
| 2021 | $125,000 | -$36.1M | -$25.5M |
Detailed financial statements for Candel Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Candel Therapeutics
4 dated milestones of Candel Therapeutics across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Candel Therapeutics is founded.
- Funding First funding round of $1.3M.
- Funding Latest funding round, Series C, of $22.5M.
- IPO Lists on the stock exchange (IPO).
Competitors of Candel Therapeutics
Candel Therapeutics has 8 listed competitors in our database, 8 of them funded. They include Replimune, TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience and GigaGen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| replimune.com | 2015 | Oxford, United Kingdom | $87M | 152 | Developer of oncolytic immunotherapies | |
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| lyell.com | 2018 | San Francisco, United States | $493M | 224 | CAR-T and TIL immunotherapies for solid tumors are developed. | |
| hummingbirdbioscience.com | 2015 | Singapore | $150M | – | Antibody drugs for cancer treatment are developed. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | |
| shattucklabs.com | 2016 | Austin, United States | $165.4M | 89 | An immunotherapy platform for oncology and other diseases is developed. | |
| boundlessbio.com | 2018 | San Diego, United States | $251.99M | 29 | Therapeutics for cancer are developed by targeting ecDNA. | |
| jacobiopharma.com | 2015 | Beijing, China | $55M | – | Small molecule therapeutics for cancer treatment are developed. |
Detailed competitors of Candel Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Candel Therapeutics
The website of Candel Therapeutics (candeltx.com) receives about 8.8K visits a month.
- Monthly visits8.8K
▼ 2.2% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Candel Therapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Candel Therapeutics
Complete news archive for Candel Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Candel Therapeutics
Candel Therapeutics was founded in 1999 and raised its 1st funding round 5 years after it was founded.
Candel Therapeutics is headquartered in United States.
Aguilar Estuardo is the current CEO of Candel Therapeutics.
Candel Therapeutics is a funded company, having raised a total of $110.3M across 14 funding rounds to date. The company's 1st funding round was a Grant of $500K, raised on Jun 2004.
Candel Therapeutics has 38 employees.
Candel Therapeutics was founded in 1999 in the United States. Focus is placed on the biotechnology sector, where viral immunotherapies are created to target cancer. These therapies work by lysing tumor cells to release antigens and neoantigens, which trigger in situ vaccination and activate both innate and adaptive immune responses. Operations center on research and development of such immunotherapies, with leadership provided by CEO Aguilar Estuardo.
Candel Therapeutics's top competitors include Hummingbird Bioscience, Replimune and Lyell Immunopharma.
Candel Therapeutics offers CAN-2409 and CAN-3110.
Yes, Candel Therapeutics is publicly traded on NASDAQ under the ticker symbol CADL.
Candel Therapeutics has 6 investors. Key investors include HHS, Sands Capital Ventures, Northpond Ventures, PBM Capital, and National Securities Corporation.